Publications Digest

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Larsen et al. explored potential healthcare savings in Denmark associated with the use of artificial intelligence-assisted vital signs monitoring systems. Based on the hypothesis, implementing these systems could potentially reduce the occurrence of serious adverse events in hospitalized patients. Utilizing Danish national registry data, the authors estimated economic benefits from the implementation of AI-assisted monitoring systems, highlighting significant potential savings from decreased length of hospital stay and fewer readmissions. However, the study highlighted the need for a more precise evaluation of the clinical effectiveness of AI-assisted technologies and detailed consideration of associated implementation costs.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Sareban et al. explored expert perspectives on establishing a reimbursement framework for digital therapeutics (DTx) in Austria. Through seven semi-structured interviews with Austrian healthcare stakeholders, the authors identified critical factors necessary for a viable national reimbursement strategy. These include user and prescriber acceptance of DTx, robust clinical evidence, data security aligned with European standards, and clear economic evaluation.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Urbina et al. analyzed the EUnetHTA 21 project, a European initiative designed to support the implementation of Regulation (EU) 2021/2282 on Health Technology Assessment (HTA). Conducted by 13 European HTA bodies, the project resulted in 20 guidance documents, 13 templates, and pilot Joint Clinical Assessments (JCAs) aimed at refining evaluation methods. The study highlights the importance of structured collaboration and regulatory preparedness, providing a roadmap for the future integration of HTA at the EU level.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-Based Publications Digest. In a recent publication, Chu et al. conducted a systematic review to develop an admission criterion framework for high-cost medical consumables in governmental hospitals. The study was carried out in a multi-country context and established a framework with seven first-level and 23 second-level indicators, highlighting the primacy of “Clinical Benefit,” followed by “Economic Value,” and “Organizational Impact.” This framework helps decision-makers ensure both efficient resource allocation and robust clinical outcomes.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Cimprich et al. discussed strategies of regulatory actors, particularly market authorization agencies, health technology assessment agencies, and health care procurement agencies, for integrating environmental sustainability requirements into the regulation of medicines and medical devices. Their analysis, contextualized within diverse healthcare settings, reveals significant untapped possibilities for strengthening regulatory frameworks to mitigate the ecological footprint of health technologies.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van den Broek-Altenburg et al. reviewed 20–25 years of economic value assessment approaches in healthcare, highlighting the growing focus on individual preferences over broad societal metrics in value-based care models. The study underscores the complexities of incorporating patient-specific preferences into economic evaluations, and addresses recognized limitations of QALY measures. The authors discussed emerging alternative valuation frameworks that could influence future policy and reimbursement decision-making.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent study, Puñal-Riobóo et al. developed a standardized minimum outcome dataset for left ventricular assist device (LVAD) registries to address key evidence gaps and meet the needs of Health Technology Assessment (HTA) bodies and healthcare professionals. Building on prior HTA findings from EUnetHTA, the authors conducted a structured three-round Delphi process with an expert panel of cardiologists to assess the relevance of various outcome measures. The consensus resulted in 18 key outcomes and 47 variables across seven healthcare domains, strengthening the reliability of real-world evidence and supporting more informed clinical and policy decisions.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Schweitzer et al. explored the suitability of the current German HTA dossier templates for the impending EU joint clinical assessment (JCA). The study examined how extensively safety endpoint and subgroup analyses in German dossiers were actually considered by IQWiG and the G-BA. The authors found that the current German HTA templates significantly increased the workload of HTA developers while leaving many reported outcomes unconsidered by IQWiG and G-BA. To mitigate duplicative efforts and ensure prompt availability of medicinal products in line with the EU HTA Regulation framework, the authors recommend well-defined dossier requirements, early consultations, and proactive engagement with HTA developers.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-based Publications Digest. In a recent publication, Otte et al. synthesized expert discussions on the challenges and opportunities of implementing Value-Based Healthcare and Health Technology Assessment in emerging markets.The study highlighted the importance of Real-World Evidence in biosimilar value assessment and decision-making processes. The authors proposed Multi-Criteria Decision Analysis as a tool for optimizing pharmaceutical procurement in resource-constrained settings. The findings emphasized the need for stronger interdisciplinary collaboration among stakeholders and the expansion of public-private partnerships to address healthcare access barriers and drive system-wide improvements.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, McCance et al. conducted a comparative carbon footprint analysis of disposable versus reusable surgical instruments in cataract surgery in the UK. Their findings highlighted the substantial environmental impact of single-use items, which had a 27-fold higher carbon footprint than reusable alternatives, with net carbon savings achieved after 19 or more reuses. These findings emphasize the necessity of integrating sustainability strategies into surgical workflows to mitigate healthcare's environmental footprint.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Donovan et al. conducted a qualitative interview study with 16 experts to investigate the gaps in capturing implementation costs within economic evaluations. The study revealed four key barriers: difficulties in defining, collecting, and valuing implementation costs; the lack of standardized methodologies; and the lack of multidisciplinary collaboration in enabling implementation costing. The authors advocated for standardized approaches to implementation cost estimation, emphasizing that improved methodologies could enhance confidence in economic assessments and better inform resource allocation.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Fassbender et al. examined how digital therapeutics (DTx) are being adopted across various European countries, exploring variations in regulatory pathways, reimbursement policies, and clinical validation requirements. The study emphasized the importance of co-design, ecosystem-driven approaches, and policy harmonization to facilitate broader adoption and sustainable integration of DTx into European healthcare systems. The authors proposed a structured framework to enhance DTx accessibility and adoption across European healthcare landscapes.